M&A

Clarivate Analytics to buy Decision Resources Group for $950m
Clarivate Analytics to buy Decision Resources Group for $950m
Pharmaceutical Business Review
Decision Resources Group
Clarivate Analytics
M&A
Flag link:
Boston Scientific to appeal order to finish failed $275M merger
Boston Scientific to appeal order to finish failed $275M merger
Mass Device
devices
Boston Scientific
Channel Medsystems
M&A
Flag link:
Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
Reuters
Lilly
M&A
JPMHC 2020
Flag link:
Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule
Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule
Pharmaceutical Business Review
Merck
Arqule
M&A
Flag link:
Think JPM seemed slow this year? You're not alone—and here's why
Think JPM seemed slow this year? You're not alone—and here's why
Fierce Pharma
JPMHC 2020
M&A
Flag link:
J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and Diversity
J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and Diversity
BioSpace
JPMHC 2020
M&A
diversity
digital health
technology
drug pricing
Flag link:
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics
Fierce Biotech
JPMHC 2020
BioNTech
Neon Therapeutics
M&A
Flag link:
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
Fierce Biotech
JPMHC 2020
M&A
Gilead Sciences
Bristol-Myers Squibb
Flag link:
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
Fierce Pharma
JPMHC 2020
Teva Pharmaceuticals
Novartis
Gilead Sciences
M&A
Pharma CEOs
Flag link:
#JPM20: Vertex lays out post-CF ambitions as Gilead demurs on acquisition
#JPM20: Vertex lays out post-CF ambitions as Gilead demurs on acquisition
Endpoints
Vertex Pharmaceuticals
cystic fibrosis
JPMHC 2020
Gilead Sciences
M&A
Flag link:
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
Fierce Pharma
M&A
JPMHC 2020
Bristol-Myers Squibb
Celgene
Giovanni Caforio
Flag link:
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Flag link:
No sleep, exiled mattresses, cleared bank accounts: Getting deals done at JPM
No sleep, exiled mattresses, cleared bank accounts: Getting deals done at JPM
Fierce Biotech
JPMHC 2020
M&A
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
5 biotech trends to follow in 2020
5 biotech trends to follow in 2020
BioPharma Dive
biotech
M&A
drug launches
JPMHC 2020
Flag link:
AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
Fierce Pharma
AbbVie
Allergan
antitrust
M&A
brazikumab
Europe
Flag link:
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
BioSpace
Eli Lilly
Dermira
dermatology
M&A
atopic dermatitis
Flag link:
Medtronic Buys Spinal Cord Therapy Company, Adding To Its Chronic Pain Management Platform
Medtronic Buys Spinal Cord Therapy Company, Adding To Its Chronic Pain Management Platform
Motley Fool
devices
Medtronic
Stimegenics
Spinal Cord Stimulation
chronic pain
M&A
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1
Pharmaforum
Almirall
Bioniz
skin cancer
alopecia
BNZ-1
M&A
Flag link:

Pages